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Background Cervical cancer is the fourth most common cancer among women, 
accounting for 10% of all female cancers and 7.5% of all cancer deaths worldwide. 1,2 
Human papillomavirus (HPV) has been detected in up to 99.7% of cervical cancers, 
making it the primary risk factor for the development of cervical cancer.3 Current 
guidelines recommend a screening test which includes a combination of cervical 
cytology as well as HPV co-testing in women over the age of 30, with HPV testing not 
recommended in women younger than the age of 30.11 The Food and Drug 
Administration has approved primary HPV testing as a screening test for cervical 
cancer, however this practice has not yet been adopted by the United States. 
Continuing to use both methods for screening purposes may lead to discrepant results 
which can be confusing for both the patient and the provider.12  
Objective To determine the diagnostic efficacy of cervical cytology versus primary HPV 
testing as screening tests for cervical dysplasia  
Methods A Scopus and Pubmed search was conducted using the following search 
terms and filters: “HPV screening versus cytology NOT home,” “within 5 years,” “full test 
article” and “English.” Articles were screened and assessed for eligibility based on study 
design, sample size, year of publication, participant characteristics, and study 
objectives. Three articles were chosen for review. 
Conclusion 
Primary HPV testing may increase accuracy of referral for colposcopy and therefore 
cervical intraepithelial neoplasia (CIN2+) diagnoses as compared to cytology. However, 
these conclusions are based on diagnosis rates after colposcopy referral and therefore 
do not address possible false-negative screening results in patients who have non-HPV 
related lesions at the time of screening. Currently, there are also no clinical or 
pathologic features that may guide clinicians in determining which patients may present 
with false-negative screening results. Further study can focus on addressing this group 


















Abbreviations and Acronyms: 
HPV     human papillomavirus  
HR-HPV  high risk-human papillomavirus 
CIN      cervical intraepithelial neoplasia 
Pap      papanicolaou 
LBC     liquid based cytology  
HC2     hybrid capture 2 
PCR     polymerase chain reaction 
OB      obstetrics  
ASCUS    atypical squamous cells of undetermined significance 
LSIL     low-grade squamous intraepithelial lesions 
LA PCR   linear chain polymerase chain reactions  
HSIL      high-grade squamous intraepithelial lesions 
OHR     other ‘high risk’ 
DS     dual stained 





Cervical cancer is the fourth most common cancer among women, accounting for 
10% of all female cancers and 7.5% of all cancer deaths worldwide. 1,2 Human 
papillomavirus (HPV) has been detected in up to 99.7% of cervical cancers, making it 
the primary risk factor for the development of cervical cancer.3 HPV infection is very 
common with an estimated life-time risk of 80% in the general population. The highest 
incidence of infection occurs in young women, at the mean age of 25 years old. The 
prevalence of high-risk HPV infection (HR-HPV) in this age group can be as high as 
60%.4 Approximately 70-90% of HPV infections remain asymptomatic and resolve within 
1-2 years without intervention.5 Those who cannot resolve the infection spontaneously 
may go on to develop high-grade cervical neoplasia due to persistent active infection 
which may occur decades after initial exposure. Due to this active infection, there may 
be continued cell activation along with loss of p53 tumor suppressor gene. The loss of 
p-53 mediated DNA repair may lead to mutations in the normal genome which can 
progress to cancer.4  
The progression from high grade cervical dysplasia within the epithelial cells of 
the uterine cervix to cancer is a long process. Cervical cancer can be divided into two 
different histotypes: squamous cell carcinoma which is responsible for 70% of cervical 
cancers and adenocarcinoma which is responsible for 15-20% of cervical cancers. 
Squamous cell carcinoma develops through precursor cells called cervical intraepithelial 
neoplasia (CIN), with the neoplastic cells being classified as 1-3, with 1 being mild and 3 
being severe dysplasia. There is less known information regarding any precursor cells 
for adenocarcinoma.6  
There are 200 different genotypes of HPV and the International Agency for 
Research on Cancer states there are 12 genotypes that are carcinogenic to humans, 
with genotypes 16 and 18 being having the highest association with high grade cervical 
intraepithelial neoplasia and the two most frequent genotypes leading to cancer. 5 A 
HPV vaccine was implemented in 2006 as a bivalent vaccine to cover 2 genotypes, 16 
and 18, and has since improved to cover 9 different genotypes. Although efficacy of the 
vaccine has proven to be up to 90-100%, there are 
still other carcinogenic genotypes that are not 
covered by the vaccine. For this reason, screening 
tests for cervical cancer are still necessary.7  
Cervical cancer screening has greatly reduced 
the mortality related to cervical cancer as it allows for 
identification of cervical dysplasia/precursor lesions 
before cancerous cells develop.8 The two different 
types of tests involved in cervical cancer screening 
are the Papanicolaou smear (Pap smear), which is a 
cytologic test and HPV DNA testing. The Pap smear, 
which was introduced to use in cervical cancer 
screening in the 1950s, may involve conventional 
cytology or liquid-based automated cytology. 
Conventional cytology involves transferring the 
collected uterine cervical sample to a slide and 
interpreted by a cytotechnologist. Liquid-based  Figure 1: Bethesda System Nomenclature10  
 
cytology (LBC) involves placing the cervical sample into a liquid to make a suspension 
which will later be interpreted in a laboratory by an automated computer system.9 
Cytologic abnormalities are typically described and classified according to the Bethesda 
System nomenclature as described in figure 1.10 The HPV test uses molecular 
technology to detect the genome of the uterine cervical cell sample. The test can be 
either non-amplified or amplified, which is usually used in clinical research and includes 
the hybrid capture 2 (HC2) and polymer chain reactions (PCR).2  
Current guidelines recommend a screening test which includes a combination of 
cervical cytology as well as HPV co-testing in women over the age of 30, with HPV 
testing not recommended in women younger than the age of 30.11  The Food and Drug 
Administration has approved primary HPV testing as a screening test for cervical 
cancer, however this practice has not yet been adopted by the United States, possibly 
due to the fear of false negative results or false positive results leading to more 
unnecessary tests. However, continuing to use both methods for screening purposes 
may lead to discrepant results which can be confusing for both the patient and the 
provider.12  Examining the efficacy of primary HPV testing in the detection of cervical 




Population: females ages 21-65 
Intervention: HPV screening  
Comparison: screening cytology on Pap smear 
Outcome: increased efficacy of diagnosis of cervical intraepithelial neoplasia   
 
Question: Among females ages 21-65, does the use of HPV screening as compared to 
cytology screening increase the efficacy of diagnosing cervical intraepithelial neoplasia?  
 
Methods:  
In September 2017, an initial Pubmed and 
Scopus database search was conducted using 
the key terms “HPV screening versus cytology 
NOT home,” with other criteria including “within 5 
years,” “full test article” and “English.” 202 articles 
were found and 154 articles remained after 
duplicates were excluded. Twelve of these 
articles were closely screened and three were 
excluded due to having little relevance to this 
current study, two being simulation studies and 
one was a cost analysis. Nine full-text articles 
were assessed for eligibility. Six of these articles 
were excluded due to the following reasons: 
studies determining efficacy of HPV cotesting 
rather than primary HPV screening, literature 
reviews, and determining obstetrics outcomes 
related to screening techniques. One 
retrospective cohort and two randomized control 
studies were included in this study due to the 
large sample sizes, participants similar to this 
study population, and these studies had 
objectives to determine the efficacy of HPV 
testing as primary screening as compared to 





Human papillomavirus testing versus cytology in primary cervical cancer screening: 
End-of-study and extended follow-up results from the Canadian cervical cancer 
screening trial.1  
 
Objective: 
Cervical cancer screening has mostly been based on cervical cytology. However, given 
the causative relationship between HPV infection and cervical carcinogenesis, this 
study considers the diagnostic accuracy of HPV testing.  The accuracy of detection of 
CIN2+ was compared for HPV testing and cytologic testing in women participating in 
primary cervical cancer screening. 
 
Study Design: 
The study is a randomized controlled trial that was conducted during the period of 2002 
and 2005. Women aged 30–69 years who sought routine cervical cancer screening in 
any of the 30 participating clinics in the greater Montreal area or St. John's were invited 
to participate. In total n = 10,154 women were willing and eligible to enroll in the trial as 
 
Figure 2: PRISMA Flow Chart13 
Abbreviation key: HPV- human papilloma virus, OB: 
obstetric  
 
described by the inclusion and exclusion criteria in table 1. The women were then 
randomized into either HPV testing or Pap cytology. 
 
 
Both study groups received both screening tests for ethical reasons, however the 
order in which the test were collected was randomized. This allowed maintenance of the 
standard of care for the participants which allowing the study team to assess the 
performance of the tests as if performed alone. The study had a blinding mechanism at 
three different levels. The participating women were not aware of the study group 
allocation. The cytotechnologists and cytopathologists evaluating Pap smears were 
unaware of inclusion of women into the study. Comparably, colposcopists and 
pathologists evaluating biopsy specimens were blinded to initial screening test results. 
Each study arm had no access to test results of each other. 
Pap smears were obtained and interpreted by cytotechnologist or 
cytopathologists and reported according to the Bethesda System nomenclature (Figure 
1). HR-HPV testing was performed using the HC2 test. Positive HR-HPV tests were 
then further examined using the Linear Array HPV Genotyping Assay. Authors reported 
HR-HPV genotypes as HPV+.  
In the initial screening process, women who tested positive either on Pap smear 
or HPV test, underwent a colposcopic exam at participating clinics. If colposcopy biopsy 
specimens revealed a histologic diagnosis of CIN2+, the women were withdrawn from 
the study and managed appropriately. If colposcopy revealed CIN1 or no lesion, these 
patients received a repeat colposcopy in 6 months. In order to avoid verification bias, 
which is a bias in testing that may occur when participants are chosen because they 
have previously undergone the test of interest that is being evaluated and agree to 
subsequently undergo the reference standard test, a total of 30% of patients who had 
negative initial testing were selected for colposcopy.14 Women not chosen for 
colposcopy were invited to receive repeat Pap smear testing at 12-18 months. This 
allowed for detection of prevalent lesions as well as lesions missed at initial enrollment. 
During the study, women received annual cytology as per cervical cancer screening 
guidelines. Women with atypical squamous cells of undetermined significance (ASCUS) 
Pap smear results received repeat Pap smear before colposcopy whereas women with 
low-grade squamous intraepithelial lesion (LSIL) Pap smear result were referred 
immediately for colposcopy. In 2008, HPV testing was introduced for patients over the 
age of 30 and therefore guidelines changed to recommend cytologic testing every 3 
years after 3 consecutive normal Pap smear results. Colposcopy referral changed to 
include ASCUS HPV+ results while patients with HPV negative results were allowed to 
return to routine screening protocol.   
Participants from St. John's were followed up for extended period from study 
enrollment date until December 31, 2013. The data on cervical cancer screening-related 
procedures and their outcomes were retrieved from the provincial database for the 
5,754 women in the area who participated in the trial. The reasons for extended follow 
up study was the availability of well organized and comprehensive  healthcare 
databases in Newfoundland. 
This study compared the predictive value of the Pap smear and HPV test by 
using the Kaplan-Meier method which is a graphical display of survival data from a 
randomized controlled trial. This method uses survival probabilities to predict time to 
event in order to compare 2 groups, and log-rank test, which uses the p-value of a study 
to determine if the null hypothesis can be rejected.14 Time-to-event was defined as time 
from the first visit to date of first histologic diagnosis of CIN2+. HPV status was also 
examined to determine predictive value of separate HPV genotypes.  
 
Results 
The average follow-up times during the protocol-defined follow-up period were 
16.6 and 12.9 months for Montreal and St. John's participants, respectively. For 
participants of the extended follow-up, the average time was 100 months. 
In general, during the initial screening, there was more probability to test positive 
on HPV than Pap smear in all study populations and regions. Among women screened 
at enrollment with a valid test, it was more common to have a positive HPV test as 
compared to Pap smear with 6.1% tested positive for HR-HPV and 2.9% tested Pap+ 
(appendix 1). Additionally, of all the women who tested HPV+ 18% of them were also 
Pap+. 
Throughout the initial screening and follow up, there were a total of 82 cases of 
CIN2+ (median age = 36 years). The majority of cases were HPV+ as compared to 
Pap+ results (82.9% versus 44.4%). This pattern was also observed in the group of 
patients with discrepant test results, as there were more patients with HPV+/Pap- than 
HPV-/Pap+ results (43.2% and 4.9% respectively). For the St. John's extended follow-
up participants, additional 30 cases of CIN2+ were diagnosed, and (54.2%) were HPV+ 
at enrollment, whereas only 19.3% were Pap+. The HPV genotype-specific tests were 
conducted using HC2 and linear array polymerase chain reaction (LA PCR). Among the 
9,988 women, about 104 (1.0%) were HPV16+, 37 (0.4%) were HPV18+, 277 (2.8%) 
were positive for HR-HPV types other than HPV16/18, and 64 (0.6%) were positive for 
HR-HPV types not in HC2, but tested by LA PCR and 9,506 (95.2%) were HC2− 
(appendix 2).   
The cumulative risks for CIN2+ detection following initial screening result of 
abnormal cytology or HPV testing were observed. Three year risk for CIN2+ following 
high-grade squamous intraepithelial lesion (HSIL) or worse result on cytology was 
significantly higher than risk associated with LSIL (p=0.02) or negative cytology 
(p=<0.0001). There was also a significant difference in associated risk of LSIL result as 
compared to normal cytology (p<0.0001). The three year risk of CIN2+ diagnosis for the 
HPV test showed significant difference between the HPV+ and the HPV- groups 
(p<0.0001). These results are displayed in figure 3. Risk associated with Pap+/HPV+ 
was significantly higher than discrepant test results (35.77% versus 8.96% HPV+/Pap- 
and 2.73% HPV-/Pap+), and abnormal cytology helped to further stratify risk in those 
patient with HPV+ result. 
During the extended follow-up period, risks, associated with results of either Pap 
cytology or HPV testing at initial screening had a trend similar to those of protocol-
defined period. However, there were no significant differences in risks between women 
with HSIL versus LSIL Pap cytology. Overall, 10-year cumulative detection of CIN2+ 
ranged from 1.15% for HPV−/Pap− women to 26.05% for HPV+/Pap+ women (appendix 
3).  
 Genotype specific results were also observed and showed a dramatic increased 
risk for patients with HPV16+ result as compared to HPV+ result with genotyping other 
than 16/18 (p=<0.001). There was no significant difference in HPV16+ versus HPV18+ 
results (p=0.19). The three year risk associated with HPV16+ was 43.84% as compared 
to 0.90% for patient with HC2- results. These estimates of risk were higher than those 
associated with Pap+ or HPV+ results. Extended follow-up results of 10 year risk 
associated with HPV genotyping results were again similar to the protocol-driven follow-
up results, with risk associated with HC2- at 1.13% as compared to HPV16+ at 
32.78%.   
 
 
Figure 3: Risk for CIN2+ is portrayed on y-axis as percent of patients with CIN2+ diagnosis while the x-
axis represents time.1 
Figure 3a shows risk for CIN2+ diagnosis during protocol-defined follow-up period associated with results 
of Pap cytology. Figure 3b shows risk for CIN2+ diagnosis during protocol-defined follow-up period 
associated with results of HPV testing. 
Abbreviations: CIN: cervical intraepithelial neoplasia, Pap: Papanicolaou   
 
Study critique: 
This study tried to address the perceived advantage of HPV testing over Pap 
smear in primary screening of cervical cancer, and the authors have done a good job in 
trying to quantify a measurable outcome. However, the validity HPV genotyping in 
predicting development of cervical cancer and guiding medical management of women 
with HR-HPV+ but normal cytology results the data is inconclusive. The reason is that, 
although the utilization of genotyping has the potential for identifying the high risk 
genotypes and improve the way we manage the patients with HR-HPV+, availability 
statistical data is still limited. The authors of the study recommended larger scale study. 
Another concern with this study is the practicality of the testing methods they 
used. In the study population, the standard screening procedure is for women with 
HPV− and Pap− results in no further colposcopy testing is recommended. However, in 
the study to correct for verification bias they standardized colposcopy protocol, thereby 
increasing the chances of detecting CIN2+ and decrease the chances of finding 
cancerous lesions later in the lives of these women (because the early detection of 
abnormal lesions by colposcopy). Therefore, their recommendations should be taken 
with a little bit of caution, and the authors address this in their discussion. 
Finally, the study was conducted in the Canadian population with some 
similarities to the US population in terms of geographical proximity and possibly the 
population composition. For this reason, the results of the study may be applicable to 
the US patients. However, it is important to note that the healthcare system is different 
in terms of availability and continuity between these two countries. As an example, in 
the above-mentioned study population, health care is government mandated and they 
had an ample access to health care. As a result, relatively extensive medical records 
were available for the study. In comparison, the availability of healthcare coverage in 
the US is not comparable to that of Canada’s. Therefore, the conclusion of the study 





Cervical screening with primary HPV testing or cytology in a population of women in 
which those aged 33 years or younger had previously been offered HPV vaccination: 
Results of Compass pilot trial randomised control.15  
 
Objective: 
Most studies about efficacy primary HPV testing for cervical screening in 
comparison to the traditional cytology (Pap smear) have been on populations with little 
or no previous access to HPV vaccination. Therefore, this study is done to assess the 
improved performance of primary HPV testing for cervical screening in detection of 
high-grade cervical intraepithelial neoplastic lesions (defined as CIN2+) and invasive 




The Compass is an open-label randomized trial of 5-yearly HPV screening that 
consisted two-arms versus 2.5-yearly liquid-based cytology (LBC) screening. An open-
label randomized trial means the clinical trial was conducted without an attempt to 
disguise the treatment/ screening options and therefore the researchers and the 
patients were aware of the type of screening they received.  A total of 5,006 eligible 
women (as described in Table 2) were recruited from 29 October 2013 to 7 November 
2014; of these, 22% were in the group age-eligible for vaccination that is women <30 
years of age.  
  
Initially, consenting women aged 25–64 years presenting for routine screening at 
47 primary practices in Victoria, Australia were included in the study and a cervical 
sample was collected. The samples were then randomized at a central laboratory at 1 to 
2 to 2 ratio allocations to the three arms of the study: (i) image-read LBC screening with 
HPV triage of low-grade cytology (‘LBC screening’), (ii) HPV screening with those 
HPV16/18 positive referred to colposcopy and with LBC triage for other oncogenic or 
other ‘high risk’ (OHR) types (‘HPV+LBC triage’), or (iii) HPV screening with those 
HPV16/18 positive referred to colposcopy and with dual-stained (DS) cytology triage for 
OHR types (‘HPV+DS triage’). In other words for every one patient assigned to the LBC 
screening, two patients each were assigned to ‘HPV+LBC triage’, and to ‘HPV+DS 
triage.’ Study groups and management for each group are shown in figure 4.  
The initial recruitment process employed two-tier blinding and randomization: the 
participating women and recruiting personnel were blinded to randomization 
assignment. Then, following the receipt of the LBC sample at the centralized laboratory, 
participants were randomized based on a computer-generated schedule. 
The computer-generated schedule was an independent design by the Australian 
government National Health and Medical Research (NHMRC) Clinical Trials Centre at 
the University of Sydney. Furthermore, the randomization used a minimization 
procedure stratified by age group <30 and 30+ years; in order to try to stratify those 
patients who likely received HPV vaccination. This was meant to ensure a good balance 
between the three arms across the stratification levels, as well as overall. Laboratory 
personnel were only made aware of the study groups after receipt and proper logging of 
each sample in order to maintain blinding.  
ThinPrep cytology was used for LBC and the 2 methods for HPV screening 
included HC2 for 22% of participants and Cobas for the initial 78% of participants.  For 
dual-stained cytology testing, CINtec PLUS technology was used, which stains for the 
markers p16 and Ki67. Australian screening recommendation for cervical cancer 
screening were followed and included cytology every 3 years and HPV screening every 
5 years. In order to correct a potential verification bias a proportion (16%) of all women 
not referred to colposcopy were randomly selected and invited for verification 
colposcopy performed at the Royal Women’s Hospital, Melbourne. However, the 
participation of rate of the women invited was very low to be a representative of an 
impartial sample. 
Statistical analysis of all eligible participants (minus the withdrawals) was done 
using Mantel–Haenszel test, a statistical significance test analysis where the null 
hypothesis states that no difference exists between the overall life table results for the 
study and control group.14 This test compared the colposcopy referral rates and CIN2+ 
detection rates in the LBC screening arm with those in the combined HPV screening 




Of the total number of 5,303 participants initially recruited, 297 women were 
ineligible and excluded from the study.  5,006 participants were randomized to the 
different study arms. 998 were assigned to LBC screening, with 3 withdrawing before 
analysis. 1,996 were assigned to arm 2 of the study and 4 participants withdrew before 
analysis. Finally, 2,012 participants were assigned to the third study arm, with 4 
participants withdrawing before analysis. Therefore, data was collected on a total of 
4,995 participants. The randomization of the study participants is described in Table 3.  
 
Table 3: Case numbers and rates of detected CIN2+ 
 
The final results were classified by the initial observed high-grade cytology rate, 
colposcopy referral rate, overall confirmed CIN2+ and CIN3+ rates in each group, and 
the overall colposcopy referral rate and detected CIN2+ rate (including 12-month follow-
up) in young women previously age-eligible for vaccination, and older women (age-
ineligible for vaccination).  
As the numbers of detections increased so did the numbers of colposcopy 
referral rate. The referral rates were classified into those referred based on the primary 
screening test, a positive triage test, or those detected at 12-month follow-up. Overall 
181 women were referred for colposcopy and histologic outcomes were available for 
177 of these participants. However, there was no clinical significance found between 
referral rates of LBC screened participants as compared to all HPV screened 
participants (referral rates displayed in figure 4). Also, after 12 months there was no 
clinical significance in referral rate of the 2 different kinds of HPV testing. There was, 
however, clinical significance when compared to historical data of colposcopy referral 
rates in Victoria in 2013. LBC referral rates were significantly lower than this reference 
rate (p=0.02) and the HPV+DS referral rate was significantly higher (p=<0.001).  
 
 
Figure 4: Referral rate for colposcopy in Study 2 
y-axis: percent of patients in each screening group referred for colposcopy; x-axis: different basis 
for referral. Abbreviations: HPV: Human Papillomavirus, LBC: liquid based cytology; DS: dual-
stained 
 
In the initial screening, the observed percentage of high-grade cytology was 
0.1% in LBC screening group. The rate of detection then jumps by 13x to 1.3% of 
participants were HPV16/18 positive in the HPV+LBC triage group.  The overall 
confirmed CIN2+ rates in each group, LBC screening, HPV+LBC triage, and HPV+DS 
triage groups, were 0.2%, 1.7%, and 2%, respectively. This shows that it is 10x more 
likely to detect CIN2+ rates by HPV-screened women combined than the LBC-
screened, but no significant difference was identified between overall CIN2+ rates in the 
2 HPV-screened groups after adjusting for HPV vaccination eligibility. The overall 
colposcopy referral rate and detected CIN2+ rate (including 12-month follow-up) is 
higher in the HPV-screened women than in the LBC screened.  
 
 The overall CIN2+ and CIN3+ rates in each colposcopy referred group was 
observed to determine the accuracy of referral for each test. There was a significant 
difference identified between the CIN2+ rates in the LBC-screened versus all HPV-
screened patients (p=0.003). On the other hand, there was no clinical significance found 
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HPV + DS triage Screening (N=2008)
 
Figure 5: CIN2+ result rates after colposcopy in Study 2 
y-axis: percent of patients with positive CIN2+ after colposcopy referral. x-axis: different study groups as 
defined as possible HPV vaccination or no HPV vaccination and total CIN2+ result. Abbreviations: HPV: 
human papillomavirus, LBC: liquid based cytology; CIN: cervical intraepithelial neoplasia DS: dual-stained  
 
During the follow up for adverse events a total of four deaths were reported, two 
deaths from each HPV+LBC, and HPV+DS triage groups. These events were reviewed 
by the trial Independent Data and Safety Monitoring Committee (IDSMC), and ruled out 
as unrelated to the trial. Additional two adverse events, one each from LBC screening 
group & the HPV+LBC triage group. These were miscommunication issues involving 
screening results, rather than related to clinical findings. 
 
Study critique: 
This study is very applicable as one of the first studies examining efficacy of 
different cervical cancer screening methods to include a highly HPV vaccinated 
population. The study tried to incorporate a population with similar demographics to 
those presenting for cervical cancer screening, however it was noted that this study 
contained a smaller percent of patients in the 25-29 age group as compared to reported 
screening demographics for Australia. This may be important when considering the 
clinical application of these results as this age group may represent a large number of 
women who have received the HPV vaccine.  
Researchers also tried to consider the possibility of HPV vaccination during the 
randomization into the different arms of the study as it included similar percentage of 
women offered HPV vaccination into each arm. This allowed for the study to also 
determine accuracy rates in patients offered vaccination. However, the study could only 
determine possibility of vaccination based on the patient’s age since vaccination status 
of each patient was not provided.  
A low rate of CIN was detected by LBC as compared to previously reported rates 
in 2013. This prompted researchers to re-read each result through an outside laboratory 
to make sure there were no errors in diagnosis. There was also a significantly high rate 
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LBC Screening: CIN2+ detection rate
HPV + LBC triage Screening: CIN2+ detection rate
HPV + DS triage Screening: CIN2+ detection rate
these rates to the historical data as this study did not include any women who are under 
surveillance for previous abnormal results but rather includes a population of well-
screened women. Therefore, this may limit the application to the general population.  
Finally, this study focused on positive predictive value of initial tests after the 
referral to colposcopy. Positive predictive value meaning the proportion of individuals 
with a positive test who actually have the disease as measured by the reference 
standard. This is the probability of having an abnormal diagnostic test if the screening 
test is positive.14 This only included 181 patients and does not address the accuracy of 
the screening test in terms of false-negative results that would therefore not be referred 
to colposcopy.  
 
Study 3 
Discrepant HPV/Cytology Cotesting Results: Are There Differences Between Cytology-
Negative Versus HPV-Negative Cervical Intraepithelial Neoplasia?12  
 
Study Objective 
        To compare characteristics of HSIL (specifically categorized as CIN3+) after 
negative cytology but positive HR-HPV (negative for intraepithelial lesion or malignancy 
[NILM]/HPV-positive) with characteristics of HSILs after negative HR-HPV but positive 
cytology (ASCUS positive/HPV negative). The reason for these discrepancies was 




        This is a retrospective cohort study in which results were retrieved through a 
computer-based search using Cerner Millennium health information system (Kansas 
City, Kansas) for women who underwent both LBC screening and HPV testing from 
January 2010 through December 2013. This included 15,173 women ages 25-99. 
ThinPrep Pap test specimens were prepared and initially interpreted by 
cytotechnologists and pathologist and then independent retrospective review was 
performed by 2 pathologists who were blinded to both the initial cytologic diagnosis as 
well as the surgical pathological diagnosis. HPV testing included reflex HPV testing, 
HPV cotesting for women over 30 years old or HPV tests that were requested for 
patients under 30 years old for unknown reasons. This testing was performed in 
residual PreservCyt vials using the Cobas 4800 system which tests for HPV types 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The results of this HPV test is 
reported as either positive or negative with further characterization of the specific 
subtypes in test that are HR-HPV positive. 
Histopathologic diagnosis of HSIL, specifically categorized as CIN3+, was made 
on hematoxylin and eosin-stained histopathologic specimens from endocervical 
curettage, biopsy, loop electrosurgical excision of the uterine cervix and hysterectomies. 
Again, an independent retrospective review by 2 pathologists was used to confirm the 
original diagnosis. Immunohistochemical analysis evaluated for the expression of p16 in 
formalin-fixed, paraffin-embedded cervical biopsy specimens using CINtec cyclin-
dependent kinase inhibitor 4A histology kit and an automated Ventana BenchMark 
ULTRA system. Results were defined as positive with the presence of both cytoplasmic 
and nuclear staining. 
Statistical analysis was performed using the XLSTAT and SPSS software by 
analyzing both variance and chi-square tests for clinical and pathologic features and 
were considered significant at P<0.05. 
 
Results 
        Of the 15,173 women screened with both Pap smear and HR-HPV, 2,944 women 
had a cytologic finding of ASCUS or greater. Within this group of women with abnormal 
cytology, 2,200 women tested positive for one of the HR-HPV subtypes. 1,184 of these 
women had histopathologic follow up and a total of 84 of these women had CIN3 
positive results. 55 patients tested ASCUS-positive/HPV-positive, 11 tested 
NILM/HPV+, 10 tested ASCUS-positive/HPV-, 3 tested NILM/HPV-, and 5 tested 
unsatisfactory.  
 
Table 4: Clinical parameters measured and results for Study 3 
 
        Clinical and pathologic parameters were investigated for the 24 patients who had 
discrepant cytology/HPV results as displayed in table 4. These parameters included 
patient age, patient race, history of screening, time to diagnosis, lesion size and 
presence of viral cytopathic changes. Each of these parameters were examined for 
each group individually and then compared overall. 
 
Cytology-positive/HPV- 
Ten patients with CIN3+ histology had positive cytology with negative HPV 
screening. The clinical parameters observed are shown in table 4. On review of 
pathology, one patient was excluded due to unavailability of the initial biopsy for review. 
Two women from this result group were diagnosed endometrial cancers extending into 
the cervix and therefore were excluded from further discussion. The remaining 7 
patients were examined and the average age, lesion size and time to occurrence were 
documented as provided in table 4. 
 
NILM/HPV+ 
Eleven patients had normal cytology with positive HPV co-testing. The clinical 
parameters for these patients are displayed in table 4. Upon review of cytology, six of 
the screening cytology results were reclassified as ASCUS, and this was attributed to 
interpreter error. The five other patient results remained classified as NILM and were 
attributed to cytologic sampling error.   
 
NILM/HPV- 
Three women had CIN3+ on histology after NILM/HPV- screening. Clinical 
parameters for these patients are discussed in table. After pathological review, there 
was no reclassification of cytology or pathologic results. One patient, who presented 
initially with postmenopausal bleeding, was diagnosed with endometrial 
adenocarcinoma. 
 
There was no significance detected in the clinical or pathologic features in the 




This study is a retrospective cohort study. This is an observational study design 
in which participants in the study are enrolled and studied after the outcome which is 
being observed has already occurred.14 For this study specifically, investigators 
reviewed the medical records of patients that met criteria for the study after the Pap 
smears and HPV testing were already performed. They reviewed the results of these 
tests after the outcome already occurred. Confounding variables, which are differences 
in the different study groups that could potentially affect the outcome, were minimized 
by having specific inclusion and exclusion criteria for the study participants. However, 
not all confounding variables can be addressed in these studying which remains a 
disadvantage of this study design. Since the outcomes of this study has already 
occurred there may be some confounding variables of which the researchers were not 
aware at the time they were reviewing these patient records.  
This type of study is beneficial for the objectives of the study because it is an 
observational study, meaning researchers are observing data rather than using any 
interventions in the study groups. The objective of this study, to compare accuracy of 
screening tests, does not need any type of specific intervention as investigators are 
observing the results of the two screening tests and the accuracy in predicting abnormal 
diagnostic testing. This type of study is beneficial in terms of the study’s objectives 
because researchers are able to look at previous records and record incidence of 
abnormal Pap smear results or HPV test result after patients had an abnormal follow up 
diagnostic test.  
Although this study initially began with a very large sample size of 15,173 women 
receiving cervical cancer screening, only 24 of those patients had discrepant cytology 
and HPV screening results and therefore the sample size discussed in this study was 
very small. The authors do address this issue during the discussion and state that this 
small sample size may be responsible for their results being different than previous 
studies, for example other studies that noted age as a possible explanation for 
discrepancy in screening test results. The inclusion and exclusion criteria for this study 
was not clearly discussed or displayed in the study, which may lead to confusion 
regarding the non-squamous cell cancer results that were later excluded from the study. 
There is also one patient that was discussed in the NILM/HPV- group that had the Pap 
smear with HPV co-testing performed as part of her workup for postmenopausal 
bleeding. This means that the testing is no longer considered a screening test and 
should not have been included in a study examining the use of HPV as a screening test. 
The discussion of the study did address possible explanations for discrepant 
results by referring to conclusion from other studies, including low residual volume of 
the sample for the HPV testing as well as the possibility of the specific subtype of HPV 
not being screened in those discrepant cases. This enhances the analysis of this study 
and may give direction to future studies that may address these issues. The authors 
also addressed other limitations to their study, including possible bias regarding 
cytologic and pathologic review since the interpreters were aware of the CIN3+ end 
point. The authors also noted that only by including CIN3+ results in the study may miss 
many other discrepant results for patients with CIN2 and CIN1 results. Acknowledging 
these limitations may allow for better future studies regarding these screening tests.   
 
Discussion 
Three studies were chosen for review in order to examine the efficacy of primary 
HPV testing as compared to cytologic testing as screening tests for cervical 
intraepithelial neoplasia. Overviews of each of these studies are displayed in table 5. 
The first two studies were applicable to our clinical question as they examined the 
efficacy of HPV testing as compared to cytology in different populations. The third study 
explored possible clinical or pathologic features that may contribute to discrepant 
screening results. Better understanding of possible etiologies of these discrepant results 
in screening tests may allow for more individualized screening methods in certain 
populations. More accurate screening tests may lead to increased efficiency of 
screening protocols and will limit the extent of screening and diagnostic tests necessary 
for diagnosis of precancerous and cancerous lesions. 
 
Table 5: Overview of Studies 
 Study 1 
Isidean et. al 
Study 2 
Canfell et. al 
Study 3 
Tracht et. al 
Objective 
 
To compare the 
performance of HPV 
testing and Pap cytology 
in detecting CIN2+ for 
patients following routine 
cervical cancer screening 
in Canada 
 
To estimate the test 
positivity rate (colposcopy 
referral rate) and CIN2+ 
detection rates for HPV-
screened versus cytology-




characteristics of CIN3 
diagnosed after negative 
cytology but positive HR-
HPV with characteristics 
of CIN3 diagnosed after 











10,154 5,000 15,173 
Population age  
 
30-69 25-64 25-99 
Follow up period 
 
12-16 months; extended 
follow up of 100 months 
13 months 36 months 
Outcome 
 




screening may allow for 
greater disease detection 
than cytology based 
screening 
 
Primary HPV testing 
provided significantly 
increased detection of 
high grade precancerous 
lesion as compared to 
cytology in patients with 
high rates of HPV 
vaccination 
There are no significant 
clinical or pathologic 
differences between 
discrepant cytology and 
HPV testing results and 
HPV-/cytology+ results 
may be missed with 
primary HPV screening 
Critique Increased rates of CIN2+ 
detection by using a 
verification protocol to 
include some of screening 
group who may not have 
been referred to 
colposcopy based on 
screening protocol 
 
Vaccinations status of 
participants not recorded, 
assessed possibility of 
vaccination based on age 
 
Large sample size initially 
but discrepant results 
from that sample only 




The studies show the superior specificity of HPV testing as compared to Pap 
smear in detecting CIN2+ or worse after colposcopy referral. The first study also 
showed that the precision of predicting 5-year risks for HPV− women was higher than 3-
year risks for Pap- women, and was comparable to 5-year risks for co-test negative 
women. Therefore, if primary HPV testing is incorporated into cervical screening 
protocols then there may be increased accuracy of the screening tests which will allow 
for more favorable screening intervals and reduced cost. However, referral to 
colposcopy for this study was based on the co-test result and therefore may not be 
representative of primary HPV colposcopy referrals. The inclusion of normal screening 
participants in the colposcopy group may have lead to a greater detection rate of CIN2+ 
lesions that would have been missed if primary HPV testing or cytology testing were 
performed alone.  
With increased rates of HPV vaccination in the United States, the second study 
may be very applicable to determine the efficacy of HPV screening as compared to 
cytology in this population. This study showed more accurate rates of diagnosing CIN2+ 
in those patients that have been referred for colposcopy which may allow for earlier 
treatment and prevention of advancement of the lesion. As stated in the study, this has 
been examined in previous studies however this is the first study to include a highly 
HPV vaccinated population. This study also examined predictive value of HPV genotype 
testing which may be used in initial screening in order to recommend colposcopy initially 
rather than requiring cytology follow up. As compared to previous studies, this study 
found lower rates of high risk HPV infection in this HPV vaccinated population which 
also supports the use of HPV vaccination to prevent not only cervical cancer but also 
unnecessary colposcopy testing.  
The final study looked to investigate possible clinical or pathologic features for 
discrepant cytologic and HPV testing results with later diagnosis of CIN. This study 
concluded that the most common causes of discrepant results were interpretation error, 
sampling error, HPV infection with subtype not currently screened or neoplasia due to 
non-HPV related carcinoma. The study found no clinical significance in the clinical 
characteristics of the patients or pathologic parameters of the diagnosis to distinguish 
which patients may present with these discrepant results. In this study, cytology-
positive/HPV-negative accounts for 29% of discrepant results in screening tests. Since 
there were no additional clinical parameters to help determine which patients may have 
discrepant HPV or cytology results, using HPV testing as a primary screening test may 
lead to missed diagnoses of these neoplasms that are either non-HPV related or 
subtypes that are not specifically tested.     
 
Conclusion 
Primary HPV testing may increase accuracy of referral for colposcopy and 
therefore CIN2+ diagnoses as compared to cytology. However, these conclusions are 
based on diagnosis rates after colposcopy referral and therefore do not address 
possible false-negative screening results in patients who have non-HPV related lesions 
at the time of screening. Currently, there are also no clinical or pathologic features that 
may guide clinicians in determining which patients may present with false-negative 
screening results. Due to the lack of identified risk factors that may help predict false-
negative results, the authors of this study do not recommend the use of HPV testing 
alone. Further study can focus on addressing this group of patients that may present 
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Appendix 1:  Case numbers and rates for detected CIN2+ and CIN3+, by age 
eligibility for vaccination. 
 
Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or 
cytology in a population of women in which those aged 33 years or younger had 
previously been offered HPV vaccination: Results of the Compass pilot randomised trial. 








Appendix 2: Positive predictive values for CIN2+ and CIN3+, by allocation group 
and referral pathway. 
 
Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or 
cytology in a population of women in which those aged 33 years or younger had 
previously been offered HPV vaccination: Results of the Compass pilot randomised trial. 










Appendix 3: Estimated colposcopy referral rates by study group. 
 
Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or 
cytology in a population of women in which those aged 33 years or younger had 
previously been offered HPV vaccination: Results of the Compass pilot randomised trial. 
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